This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Back to overview

Marleen Kok group

Marleen Kok

Marleen Kok

Junior Group Leader

Personal details


After finishing Medical School (2004) including an undergraduate research training on neuroblastoma genetics at the prestigious University of Pennsylvania (Philadelphia, USA), Marleen Kok performed her Ph.D. research from 2004-2009 at The Netherlands Cancer Institute. Working in the labs of Laura van 't Veer (currently at UCSF) and Sabine Linn (NKI, Amsterdam), she tested the predictive value of gene signatures as well as modifications of the Estrogen Receptor to predict tamoxifen resistance. This training by true experts in the field of breast cancer biomarkers forms a solid basis to pursue her career in translational breast cancer research.

After her residency/fellowship (2009-2015) in Internal Medicine/Medical Oncology she worked as postdoctoral fellow (2015-2016) of the Dutch Cancer Society at John Hopkins University (Baltimore, USA) in the labs of Leisha Emens and Drew Pardoll. We showed that intratumoral STING (Stimulator of Interferon Genes) agonists can potently prime tumor antigen-specific CD8+ T cell responses.

In 2016 Marleen Kok returned to the NKI to work as Medical Oncologist and translational research fellow in the lab of Ton Schumacher (2016-2018), who is world-leading in the field of T cell biology. She is the lead PI of several innovative investigator-initiated breast immunotherapy trials evaluating the efficacy of PD1-blockade with (low dose) chemotherapy and since 2019 she is Group Leader at the NKI with a focus on translational breast cancer immunology.

Share this page